PMID- 24456257
OWN - NLM
STAT- MEDLINE
DCOM- 20141214
LR  - 20140418
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 36
IP  - 4
DP  - 2014 May
TI  - Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients 
      in kidney transplantation.
PG  - 585-8
LID - 10.3109/0886022X.2014.880326 [doi]
AB  - OBJECTIVE: Intravenous immunoglobulin (IVIG) products are known to have 
      beneficial immunomodulatory effects on several inflammatory and autoimmune 
      disorders. These effects could be attributed to a different inhibitory action on 
      complement factors, but other mechanisms could be implicated, e.g., 
      immunocomplexes development and/or anti-idiotypic antibodies. Positive results on 
      the reduction of anti-Human Leukocyte Antigens (HLA) antibodies in highly 
      sensitized patients have also been found. The present study focuses on the effect 
      of IVIG on the reduction of Panel Reactive Antibody level and crossmatch 
      positivity in sensitized patients awaiting kidney transplantation. METHODS: The 
      study was performed adapting an in vitro assay on sensitized patients' sera in 
      waiting list for kidney transplantation. Sera of twelve highly sensitized 
      patients were evaluated for the cytotoxicity inhibition after 10% IVIG treatment. 
      RESULTS: A reduction of anti- HLA antibody levels was observed in 75% (9/12) of 
      treated patients in vitro, while 25% (3/12) resulted unresponsiveness. 
      Particularly, our data showed a significantly higher Panel Reactive Antibody 
      reduction for T lymphocytes (p<0.010) than B lymphocytes (p<0.032). CONCLUSIONS: 
      In this study, we have used an in vitro assay to investigate susceptibility to 
      desensitization with IVIG treatment of sensitized patient sera. These findings 
      reveal that the variable effect of IVIG on reducing Panel Reactive Antibody in 
      our immunized patients could be attributed to a different inhibitory action on 
      complement, likely due to the type and the titre of anti-HLA antibodies.
FAU - Picascia, Antonietta
AU  - Picascia A
AD  - U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant 
      Immunology [SIMT], Regional Reference Laboratory of Transplant Immunology [LIT], 
      Azienda Ospedaliera Universitaria (AOU) and.
FAU - Grimaldi, Vincenzo
AU  - Grimaldi V
FAU - Paolillo, Rossella
AU  - Paolillo R
FAU - Vasco, Maria
AU  - Vasco M
FAU - Casamassimi, Amelia
AU  - Casamassimi A
FAU - De Luca, Francesco Paolo
AU  - De Luca FP
FAU - Cavalca, Francesco
AU  - Cavalca F
FAU - Schiano, Concetta
AU  - Schiano C
FAU - Napoli, Claudio
AU  - Napoli C
LA  - eng
PT  - Journal Article
DEP - 20140123
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies/*blood
MH  - B-Lymphocytes/immunology
MH  - Complement Activation/*drug effects
MH  - Desensitization, Immunologic/*methods
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*pharmacology
MH  - In Vitro Techniques
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocytes/immunology
MH  - Transplantation Immunology
EDAT- 2014/01/25 06:00
MHDA- 2014/12/17 06:00
CRDT- 2014/01/25 06:00
PHST- 2014/01/25 06:00 [entrez]
PHST- 2014/01/25 06:00 [pubmed]
PHST- 2014/12/17 06:00 [medline]
AID - 10.3109/0886022X.2014.880326 [doi]
PST - ppublish
SO  - Ren Fail. 2014 May;36(4):585-8. doi: 10.3109/0886022X.2014.880326. Epub 2014 Jan 
      23.